Endoglin in angiogenesis and vascular diseases

Area of Science:

• Vascular biology
• Cell signaling
• Molecular medicine

Background:

• Endoglin is a transmembrane receptor for transforming growth factor-beta (TGF-beta), primarily on proliferating endothelial cells.
• Endoglin deficiency leads to embryonic lethality due to cardiovascular defects.
• Mutations in endoglin and ALK1 are associated with hereditary hemorrhagic telangiectasia (HHT).

Purpose of the Study:

• To investigate the role of endoglin in vascular development and disease.
• To explore the therapeutic potential of targeting endoglin in angiogenesis-related disorders.
• To understand endoglin's contribution to pre-eclampsia and tumor angiogenesis.

Main Methods:

• Analysis of endoglin deficient and heterozygote mouse models.
• Investigation of endoglin's role in HHT-like vascular abnormalities and tumor angiogenesis.
• Study of soluble endoglin's involvement in pre-eclampsia pathogenesis.
• Evaluation of endoglin antibodies for anti-angiogenic therapy in cancer models.

Main Results:

• Endoglin heterozygote mice exhibit HHT-like vascular issues, impaired angiogenesis, and altered vascular tone regulation.
• Placental endoglin is upregulated in pre-eclampsia, with soluble endoglin contributing to endothelial dysfunction.
• Endoglin antibodies demonstrate anti-angiogenic effects against tumor-associated endothelium in mouse models.

Conclusions:

• Endoglin plays a critical role in vascular integrity and development.
• Dysregulation of endoglin is implicated in various vascular pathologies, including HHT, pre-eclampsia, and cancer.
• Targeting endoglin presents a promising therapeutic strategy for diseases characterized by abnormal angiogenesis.